

The colorectal carcinoma – treatment research and treatment reality in oncology practices

F. Strohbach¹, A. Schlichting², HW. Tessen³, Project team of Internal Oncology (PIO)

¹Specialized oncology practice Berlin, ²rgb Onkologisches Management GmbH Sarstedt, ³Specialized oncology practice Goslar

Approach

Which share does a continuous, systematic case documentation and evaluation contribute to treatment research?

Methods

Data from oncology practices from 2003-2014 (PIO), analysis of the ONCOReg. index, 7,386 histories of diseases in 123 oncology practices from 16 federal states

Results

Pat. in **UICC-state** I: 225 (3%), II: 955 (13%), III: 3,321 (45%), IV: 2,785 (38%), n/a: 99 (1%)

Gender: m: 4,434 (60%), f: 2,952 (40%)

Age: median 66 (18-92) years

Primary surgery.: 6,850 (93%) pat.

Adjuvant Ctx:

3,886 (52,6%) pat., 1,302 (34%) of which ≥70 years and 2,651 (68%) with Oxaliplatin.

Palliative Ctx:

4,861 pat. had spread metastasis.

A resection of metastasis was performed on 784 (16%) of the patients.

4,810 (99%) of the patients received a 1st-line ctx, 3,238 (67%) a 2nd-line, 1,763 (37%) a 3rd-line, 833 (17%) a 4th-line (max. 9 lines), 3,409 (72%) an antibody.

Survival

3,130 (42%) of the patients have died, loss of contact to 886 (12%) of them.

Monitoring period of adjuvant ctx ≥ 3 years: 1,402 (36%).

After adjuvant ctx: DFS (median) all therapies 42.0 mths.; ≥70 years 39,7 mths.; Oxaliplatin-based therapies 66,3 mths.; **3-year OS** (median) all therapies 76,2 mths.; ≥70 years 64,0 mths.; Oxaliplatin-based therapies 88,7 mths.

After palliative ctx: PFS: 1st/2nd-line 9.6/6.4 mths. **OS:** 1st/2nd-line 24.7/15.1 mths.

OS from initial metastasis: 27.5 mths.; with/without antibody 28.8/22.8 mths.

With/without resection of metastasis 49.5/24.9 mths.

Conclusion:

The data collected over a long period of time depict very precisely the reality of treatment in oncology practices in Germany. The evaluation presented contributes an important share to the complex of treatment research and answers a series of patient-related questions. Further evaluations will be presented regularly.